JP7247102B2 - ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用 - Google Patents

６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用 Download PDF

Info

Publication number
JP7247102B2
JP7247102B2 JP2019558390A JP2019558390A JP7247102B2 JP 7247102 B2 JP7247102 B2 JP 7247102B2 JP 2019558390 A JP2019558390 A JP 2019558390A JP 2019558390 A JP2019558390 A JP 2019558390A JP 7247102 B2 JP7247102 B2 JP 7247102B2
Authority
JP
Japan
Prior art keywords
pyrido
pyrimidin
pyridin
amine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019558390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517698A (ja
JP2020517698A5 (enExample
Inventor
ベーンケ，ディルク
ベレンシュテイン，フラダ
ハオ，シュエシ
ホフマン，ティモシー
ジン，チフア
ラコステ，アルノー
リー，キャメロン
リウ，ジュン
リウ，ヤフ
マイバウム，ユルゲン，クラウス
モ，ティンティン
パン，ジアンフェン
ク，シン
チョルズ，ジャン
フェン シエ，ユン
ヤン，シャンシャン
ゾウ，イェフェン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020517698A publication Critical patent/JP2020517698A/ja
Publication of JP2020517698A5 publication Critical patent/JP2020517698A5/ja
Priority to JP2022144957A priority Critical patent/JP2022188056A/ja
Application granted granted Critical
Publication of JP7247102B2 publication Critical patent/JP7247102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/27—Lung cells, respiratory tract cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019558390A 2017-04-28 2018-04-26 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用 Active JP7247102B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022144957A JP2022188056A (ja) 2017-04-28 2022-09-13 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762491475P 2017-04-28 2017-04-28
US201762491526P 2017-04-28 2017-04-28
US201762491573P 2017-04-28 2017-04-28
US201762491484P 2017-04-28 2017-04-28
US62/491,573 2017-04-28
US62/491,484 2017-04-28
US62/491,526 2017-04-28
US62/491,475 2017-04-28
US201862650232P 2018-03-29 2018-03-29
US62/650,232 2018-03-29
PCT/IB2018/052919 WO2018198077A2 (en) 2017-04-28 2018-04-26 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144957A Division JP2022188056A (ja) 2017-04-28 2022-09-13 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Publications (3)

Publication Number Publication Date
JP2020517698A JP2020517698A (ja) 2020-06-18
JP2020517698A5 JP2020517698A5 (enExample) 2021-06-10
JP7247102B2 true JP7247102B2 (ja) 2023-03-28

Family

ID=62148436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558390A Active JP7247102B2 (ja) 2017-04-28 2018-04-26 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用
JP2022144957A Pending JP2022188056A (ja) 2017-04-28 2022-09-13 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022144957A Pending JP2022188056A (ja) 2017-04-28 2022-09-13 ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Country Status (25)

Country Link
US (2) US11458138B2 (enExample)
EP (1) EP3615537B1 (enExample)
JP (2) JP7247102B2 (enExample)
KR (1) KR20190142776A (enExample)
CN (3) CN114703144A (enExample)
AU (2) AU2018260495B2 (enExample)
BR (1) BR112019022512A2 (enExample)
CA (1) CA3056906A1 (enExample)
CL (1) CL2019003049A1 (enExample)
CO (1) CO2019011873A2 (enExample)
CR (1) CR20190483A (enExample)
CU (2) CU20200080A7 (enExample)
DO (1) DOP2019000273A (enExample)
EC (1) ECSP19076732A (enExample)
ES (1) ES2983611T3 (enExample)
IL (2) IL269293B (enExample)
JO (1) JOP20190257A1 (enExample)
MA (1) MA49285A (enExample)
MX (1) MX2019012756A (enExample)
PE (1) PE20200292A1 (enExample)
PH (1) PH12019502436A1 (enExample)
SG (1) SG11201908615RA (enExample)
TW (1) TW201843140A (enExample)
UY (1) UY37703A (enExample)
WO (1) WO2018198077A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536436A (ja) 2015-12-04 2018-12-13 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
MX2019011272A (es) 2017-03-22 2019-10-24 Novartis Ag Composiciones y metodos para inmunooncologia.
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
US20210253518A1 (en) 2018-06-08 2021-08-19 Nissan Chemical Corporation Kinase inhibitor
PL3813800T3 (pl) 2018-06-29 2025-08-18 Incyte Corporation Formulacje inhibitora axl/mer
US20220001074A1 (en) * 2018-10-16 2022-01-06 The Schepens Eye Research Institute, Inc. Bioadhesive for Soft Tissue Repair
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
EP3896158A4 (en) * 2018-12-11 2022-11-02 Kyoto University METHODS OF INDUCING A DELETION IN GENOMIC DNA
WO2020158841A1 (ja) 2019-01-30 2020-08-06 日産化学株式会社 ヒドラジド化合物及びキナーゼ阻害剤
CN112707905B (zh) * 2019-10-25 2024-07-02 武汉誉祥医药科技有限公司 一种三并杂环化合物及其制备方法和用途
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7759877B2 (ja) * 2019-11-27 2025-10-24 ジェネンテック， インコーポレイテッド 治療用化合物
CN115515579B (zh) * 2020-02-05 2025-09-30 洛克菲勒大学 吡咯并[2,3-b]吡啶-3-甲酰胺组合物和改善听力损失的方法
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
MX2022013518A (es) * 2020-04-28 2023-02-01 Global Blood Therapeutics Inc Pirimidinas cicloalquiladas como inhibidores de la ferroportina.
CN112305126A (zh) * 2020-11-02 2021-02-02 宁夏贝利特生物科技有限公司 一种硝酸胍含量的测定方法
JP7738165B2 (ja) * 2021-08-23 2025-09-11 イー・エム・デイー・ミリポア・コーポレイシヨン 電気泳動ゲルの光重合システム及び方法
CN115974868B (zh) * 2022-11-07 2024-04-12 安徽理工大学 一种尿嘧啶衍生物的合成方法及其抗肺纤维化方面的潜在应用
WO2024211621A1 (en) * 2023-04-04 2024-10-10 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration
CN119462609A (zh) * 2024-10-25 2025-02-18 烟台皓元生物医药科技有限公司 一种lats抑制剂vt02956的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
US20110319409A1 (en) 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
WO2013012087A1 (ja) 2011-07-15 2013-01-24 国立大学法人大阪大学 角膜内皮細胞の調製方法
JP2015533822A (ja) 2012-09-28 2015-11-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
WO2017023905A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Heterocyclic compounds useful as modulators of tnf alpha
JP2017509655A (ja) 2014-03-25 2017-04-06 キャンサー・リサーチ・テクノロジー・リミテッド 非定型プロテインキナーゼｃのアザキナゾリン阻害薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
MX2009010696A (es) * 2007-04-06 2009-10-20 Novartis Ag Derivados de 2,6-naftiridina como moduladores de cinasa de proteina.
KR20140074964A (ko) 2011-09-27 2014-06-18 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
BR112016013201B1 (pt) * 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
CA2996513A1 (en) 2015-08-25 2018-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
US20110319409A1 (en) 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
WO2013012087A1 (ja) 2011-07-15 2013-01-24 国立大学法人大阪大学 角膜内皮細胞の調製方法
JP2015533822A (ja) 2012-09-28 2015-11-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
JP2017509655A (ja) 2014-03-25 2017-04-06 キャンサー・リサーチ・テクノロジー・リミテッド 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
WO2017023905A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Heterocyclic compounds useful as modulators of tnf alpha

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Shaw, Duncan; Hollingworth, Greg; Soldermann, Nicolas; Sprague, Elizabeth;Schuler, Walter; Vangrevelinghe, Eric; Duggan, Nicholas; Thomas, Matthew;Kosaka, Takatoshi; Waters, Nigel; van Eis, Maurice J.，Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension，Bioorganic & Medicinal Chemistry Letters ，2014年，24(20),，4812-4817
Wang, Peng; Yang, Yong; Shao, Qiuping; Zhou, Wenqin，Selective inhibition of ROCK kinase isoforms to promote neuroregeneration after brain surgery，Medicinal Chemistry Research，2016年，25(1)，40-50
YAWEI Hao et al.，Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP，Journal of Biological Chemistry，2008年，283(9)，5496-5509

Also Published As

Publication number Publication date
KR20190142776A (ko) 2019-12-27
IL292857A (en) 2022-07-01
JP2020517698A (ja) 2020-06-18
IL269293A (en) 2019-11-28
CR20190483A (es) 2019-11-20
ES2983611T3 (es) 2024-10-23
MX2019012756A (es) 2019-12-16
SG11201908615RA (en) 2019-11-28
US20230190751A1 (en) 2023-06-22
US11458138B2 (en) 2022-10-04
PE20200292A1 (es) 2020-02-05
CA3056906A1 (en) 2018-11-01
ECSP19076732A (es) 2019-10-31
BR112019022512A2 (pt) 2020-06-16
RU2019138304A (ru) 2021-05-28
TW201843140A (zh) 2018-12-16
WO2018198077A3 (en) 2019-02-14
RU2019138304A3 (enExample) 2021-07-13
CN114621222B (zh) 2024-12-17
UY37703A (es) 2018-11-30
EP3615537A2 (en) 2020-03-04
CU20200080A7 (es) 2021-05-12
CN110573511A (zh) 2019-12-13
CN114703144A (zh) 2022-07-05
US20180344738A1 (en) 2018-12-06
EP3615537B1 (en) 2024-03-06
CO2019011873A2 (es) 2020-01-17
AU2018260495B2 (en) 2021-09-16
WO2018198077A2 (en) 2018-11-01
JP2022188056A (ja) 2022-12-20
CU20190086A7 (es) 2020-11-30
JOP20190257A1 (ar) 2019-10-28
IL269293B (en) 2022-06-01
AU2018260495A1 (en) 2019-10-17
MA49285A (fr) 2020-03-04
CL2019003049A1 (es) 2020-02-07
CN110573511B (zh) 2023-04-25
PH12019502436A1 (en) 2020-07-20
DOP2019000273A (es) 2019-12-15
AU2021286281A1 (en) 2022-01-06
CN114621222A (zh) 2022-06-14

Similar Documents

Publication Publication Date Title
JP7247102B2 (ja) ６－６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用
US20200131474A1 (en) Methods and compositions for ocular cell therapy
JP2021035944A (ja) Ｒｅｔキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリジン化合物
TW202136251A (zh) Irak降解劑及其用途
CN104114558B (zh) 呋喃并吡啶衍生物
AU2012327954A1 (en) Novel purine derivatives and their use in the treatment of disease
JP6859549B2 (ja) 医薬品活性を有するヘテロアリール化合物
CN104254531A (zh) 环状二氨基嘧啶衍生物
US20230348852A1 (en) Methods and compositions for ocular cell therapy
CA2923765A1 (en) Stem cell modulation ii
RU2775721C2 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
EA038453B1 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
HK40055084A (en) Methods and compositions for ocular cell therapy
NZ624366B2 (en) Novel purine derivatives and their use in the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230315

R150 Certificate of patent or registration of utility model

Ref document number: 7247102

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150